伊古拉提莫德在治疗帕林德罗姆类风湿症中的有效性
Fangfang Yuan1, Junhong He2, Jing Luo1
1Department of Rheumatism and Immunology, Ningbo No. 6 Hospital, Ningbo, China.
Immunity, inflammation and disease
|June 29, 2023
概括
伊古拉提莫德 (IGU) 通过显著减少疾病爆发和疼痛,有效治疗类风湿症 (PR). 这种免疫调节器在改善PR患者的临床症状方面表现出高效.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 伊古拉提莫德 (IGU) 是一种新兴的免疫调节剂,在类风湿性关节炎中已证明有效.
- IGU的治疗潜力扩展到其他免疫媒介疾病,促使对帕林德罗姆类风湿症 (PR) 的研究.
研究的目的:
- 评估iguratimod (IGU) 在被诊断为帕林德罗姆类风湿症 (PR) 患者的疾病活动和症状管理中的疗效.
主要方法:
- 患有PR的患者被分为对照组和IGU治疗组.
- 通过监测PR攻击的月度频率,视觉模拟尺度 (VAS) 疼痛得分和整体临床症状来评估有效性.
主要成果:
- 与对照组相比,IGU组表现出明显更高的药物阳性率 (100%) 和疾病控制率 (90.91%),分别为61.11%和5.56%.
- 与对照组相比,IGU治疗导致IGU组中PR爆发和VAS疼痛得分的中位数大幅下降.
- 统计分析证实,IGU组的PR爆发频率显著降低,VAS得分有所改善 (p<0.001).
结论:
- 这项研究首次证明了伊古拉蒂莫德在治疗巴林德罗姆类风湿症方面的有效性.
- 伊古拉提莫德显著降低了PR爆发的频率,并改善了临床症状,为PR患者提供了一个有前途的治疗选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
158
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
158
Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179


